GB Patent

GB2513615A — Medical use

Assigned to Cancer Research Technology Ltd · Expires 2014-11-05 · 12y expired

What this patent protects

A molecule that modulates an activity of a Src family kinase for use in preventing or treating a metastatic cancer in a subject. Preferably, the molecule comprises the structure: Bj-[(Pro)n-Xr-His-Pro-His-Ala-Arg-Ile-Lys]m-Rp or, Bj-[lys-ile-arg-ala-his-pro-his-xr-(pro)n]m-­Rp, …

USPTO Abstract

A molecule that modulates an activity of a Src family kinase for use in preventing or treating a metastatic cancer in a subject. Preferably, the molecule comprises the structure: Bj-[(Pro)n-Xr-His-Pro-His-Ala-Arg-Ile-Lys]m-Rp or, Bj-[lys-ile-arg-ala-his-pro-his-xr-(pro)n]m-­Rp, or a derivative or fragment thereof, wherein B is a first chemical moiety, j is 0 or 1, n is an integer from 1-10, X is any amino acid, r is an integer from 0 to 2, m is an integer from 1 to 3, R is a second chemicalmoiety and p is 0 or 1. Also claimed is a composition comprising such a molecule and a therapeutic agent suitable for preventing or treating a metastatic cancer; a method of selecting an agent to prevent or treat a metastatic cancer comprising determining whether a test agent modulates an activity of a Src family kinase.

Drugs covered by this patent

Patent Metadata

Patent number
GB2513615A
Jurisdiction
GB
Classification
—
Expires
2014-11-05
Drug substance claim
No
Drug product claim
No
Assignee
Cancer Research Technology Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.